Article

Concise Synthesis of Yashabushidiol A and (±)-Diospongin A

Tse-Lok Ho,^a* Bin Tang,^b Guohua Ma^b and Pengfei Xu^b*

^aDepartment of Applied Chemistry, National Chiao Tung University, Hsinchu, Taiwan, R.O.C. ^bState Key Laboratory of Applied Organic Chemistry, Department of Chemistry, Lanzhou University, Lanzhou 730000, P. R. China

(Received: Dec. 26, 2011; Accepted: Jan. 2, 2012; Published Online: Jan. 16, 2012; DOI: 10.1002/jccs.201100664)

Synthesis of (\pm) -diospongin A has been achieved from the (2*SR*,4*RS*)-pentane-1,2,4,5-tetraol in six steps. An intermediate has also been converted into yashabushidiol A. This work features a desymmetric cyclization and reduction of a *meso*-1,7-diarylheptanoid precursor to furnish the desired *cis*-2,6-di-substituted tetrahydropyran.

Keywords: (2*SR*,4*RS*)-pentane-1,2,4,5-tetraol; Dithiane alkylation; Desulfurization; *meso*-1,7-Diarylheptanoids; Cyclization.

INTRODUCTION

Desymmetrization of *meso* substrates is a powerful strategy for acquiring chiral intermediates for organic synthesis. Recent examples include asymmetric ring opening of epoxide,¹ monoacylation of 2-substituted 1,3-propanediols,² and ring-closing metathesis that selects one of two identical double bonds.³ Our long-standing interest in design of natural products synthesis led us to consider an approach to two 1,7-diarylheptanoids in the other context of avoiding regiochemical problems.⁴

As a metabolite in the rhizomes of *Dioscorea spon*giosa, diospongin A with anti-osteoporotic activity⁵ has attracted synthetic efforts from several research groups. Routes with key reactions of cross-metathesis and intramolecular Michael addition (Cossy,^{6a} Bates^{6c}), ring-closing olefin metathesis (Jennings^{6b}), Pd(II)-catalyzed S_N2'-type reaction (Uenishi^{6d}), Prins reaction (Jadav,^{6e} Piva^{6f}) and tandem cross-metathesis/S_N2' reaction (Hong^{6g}) have been explored.

Our synthetic design is based on of the generation of the tetrahydropyran core from a *meso* dihydroxydiketone, from which cyclic hemiacetal formation involving any pair of C=O/OH yields the same product (Scheme I). In our analysis, to establish the desired *cis*-2,6-disubstituted tetrahydro-pyran system via hydride delivery from a hydrosilane to the incipient carboxonium species would be favored by stereoelectronic effects and possibly chelation of the silicon atom with the axial hydroxyl group (Scheme II).⁹ The attractiveness of this route is evident by proceeding via intermediates amenable to the elaboration of yasha-





bushidiol A, which occurs in the male flowers of *Alnus sieboldiana* Matsum,⁷ and possesses anticancer properties against certain human leukemia and melanoma cell lines. Yashabushidiol A and several cognate compounds have been synthesized.⁸

With the subgoal of our synthesis identified as dihydroxydiketone **6**. We started on its preparation from (2SR,4RS)-pentane-1,2,4,5-tetraol (**1**), which is available from D-ribose by following the procedure described for L-arabitol.¹⁰ The synthetic process is depicted in Scheme III.

Dedicated to the memory of Professor Yung-Son Hon (1955–2011).

^{*} Corresponding author. E-mail: tho@cc.nctu.edu.tw

Article

Scheme II Reductive cyclization



Scheme III



Reagents and conditions: (a) TsCl, py, DMAP, 0 °C, 36%; (b) PhCH(OMe)₂, CH₂Cl₂, r.t., 77%; (c) LDA, DMPU,-40 °C to 0 °C, 78%; (d) 80% HOAc, 60 °C, 74%; (e) MeCN/sat.NaHCO₃, I₂, 0 °C, 64%; (f) Et₃SiH, Me₃SiOTf, 0 °C, 42%; (g) HgO, BF₃.Et₂O, THF/H₂O, 82%; (h) H₂, Pd(OH)₂/C, EtOH, 35 °C, 72%.

RESULTS AND DISCUSSION

The point of departure in this work was ditosylate $2^{11,12}$ The optimal conditions we found involves tosylation of 1 in pyridine at 0 °C for 12 h, but a yield of only 36% was obtained. The next step was protection¹³ of the free hydroxyl groups in the form of a 2-phenyl-1,3-dioxane derivative. While benzylidenation with benzaldehyde was inefficient, transacetalization with benzaldehyde dimethyl

acetal proved satisfactory, 3 was produced in 77% yield.

Next, two benzal units were introduced to complete the required chain length by way of dithiane alkylation. Thus, exposure of 2-lithio-2-phenyl-1,3-dithiane that was generated in THF at -40 °C to **3** afforded the desired product **4** (78% yield). Raising the reaction temperature to 0 °C ensured complete conversion of the mono-dithianated tosylate to **4**. Desulfurization¹⁴ of **4** was performed with red HgO and BF₃ etherate in 15% aq. THF (Yield 82%).

It is evident that intermediates 4, 5, and 7 can be readily converted into yashabushidiol A (8). We arbitrarily chose 7 to complete the conversion and found the combined debenzylidenation and reduction¹³ proceed better with the Pd(OH)₂/C catalyst than the more common Pd/C; yashabushidiol A was obtained in 72% yield.

Finally, the debenzylidenation¹³ and desulfurization¹⁴ were achieved in 74% and 64% yields, respectively. The key transformation was the treament of **6** with Me₃SiOTf, then Et₃SiH, in a salt-ice bath for 15 minutes, thereby affording the target molecule (\pm)-diospongin A in 42% yield.

In summary, a consolidated synthetic route to (\pm) diospongin A and yashabushidiol A from the (2SR,4RS)pentane-1,2,4,5-tetraol (1) has been developed, featuring formation of a *cis*-disubstituted tetrahydropyran and desymmetric cyclization followed by reduction of a *meso*-1,7-diarylheptanoid.

EXPERIMENTAL

All solvents and reagents were dried prior to use. Diisopropylamine was distilled from calcium hydride, and THF from sodium benzophenone. n-Butylithium in hexane was purchased from Alfa and titrated before use. Thinlayer chromatography plates were visualized by exposure to UV light and/or immersion in a phosphomolybdic acid solution followed by heating on a hot plate. Flash chromatography was carried out utilizing 200-300 mesh silica gel. ¹H NMR and ¹³C NMR spectra were recorded in CDCl₃, or a deuterated solvent otherwise indicated, on the Varian Mercury-plus 600 or Bruck 400 M instrument, for ¹H NMR spectral data are reported in *ppm* relative to chloroform ($\delta =$ 7.26 ppm) or deuterium oxide ($\delta = 4.68$ ppm) as internal standard and ¹³C NMR data are reported in *ppm* relative to chloroform ($\delta = 77.0$ ppm) as internal standard. High-resolution mass spectral analysis (HRMS) data were measured on the Bruker Spexll by means of the ESI technique.

(2SR,4RS)-Pentane-1,2,4,5-tetraol (1)

Prepared in the same manner as described in ref. 10.

White solid; m.p. 37 °C; IR (KBr): 3381, 2940, 1648, 1421, 1224, 1059, 1142, 921, 785, 623, 586 cm⁻¹. ¹H NMR (400 MHz, D₂O): δ = 3.91-3.85 (2H, m), 3.64 (2H, dd, *J* = 12, 4 Hz), 3.50 (2H, dd, *J* = 12, 6.4 Hz), 1.75-1.68 (1H, m), 1.64-1.56 (1H, m). ¹³C NMR (100 MHz, D₂O): δ = 69.4, 65.1, 35.5. MS (ESI): (M+Na⁺) 159.

(2SR,4RS)-Pentane-1,2,4,5-tetraol 1,5-ditosylate (2)

A solution of 1 (534 mg, 3.93 mmol) in distilled pyridine (8.9 mL) at 0 °C was stirred with DMAP (48 mg, 0.39 mmol) and TsCl (1.646 g, 8.64 mmol). After 12 h the reaction was quenched with aq. HCl (2N, 20 mL) and extracted with EtOAc (3×10 mL). The combined organic solutions were dried over anhydrous Na₂SO₄ filtered and evaporated in vacuo to afford a residue which was chromatographed (CH₂Cl₂/EtOAc 6:1) to give **2** as a colorless oil.

Yield: 627 mg (36%). IR (KBr): 3415, 2950, 1738, 1358, 1175, 1097, 969, 816, 667, 554 cm⁻¹. ¹H NMR: δ = 7.78 (4H, d, *J* = 8.4 Hz), 7.36 (4H, d, *J* = 8 Hz), 4.09 (2H, dd, *J* = 8.8, 3.6 Hz), 3.93 (4H, d, *J* = 5.2 Hz), 3.37 (2H, s), 2.46 (6H, s), 1.67-1.52 (2H, m); ¹³C NMR: δ = 145.3, 132.2, 130, 128, 73, 68.9, 34.5, 21.6. HRMS (ESI): *m/z* (M+NH₄⁺) calcd for C₁₉H₂₄O₈S₂: 462.1251; found: 462.1244.

(2*SR*,4*RS*)-Pentane-1,2,4,5-tetraol 2,4-*O*-benzylidene 1,5-ditosylate (3)

To a solution of **2** (325 mg, 0.73 mmol) and PhCH(OMe)₂ (197 μ L, 1.31 mmol) in dry CH₂Cl₂ (8 mL) under argon was added camphorsulfonic acid (17 mg, 0.073 mmol). The mixture was stirred for 12 h at room temperature, evaporated under high vacuum, and chromatographed (CH₂Cl₂/EtOAc 3:1) to afford **3** as a white solid; m.p. 115 °C.

Yield: 287 mg (77%). IR (KBr): 1596, 1456, 1355, 1193, 1017, 986, 917, 808, 667, 554 cm⁻¹. ¹H NMR: δ = 7.76 (4H, d, *J* = 8.4 Hz), 7.32-7.27 (11H, m), 5.42 (1H, s), 4.09 (4H, d, *J* = 8 Hz), 4.03-4.01 (2H, m), 2.45 (6H, s), 1.48-1.40 (1H, m), 1.27-1.24 (1H, m); ¹³C NMR: δ = 145, 137.1, 132.5, 129.8, 129, 128.1, 127.9, 126.1, 100.5, 73.3, 71, 28.6, 21.6. HRMS (ESI): *m/z* (M+NH₄⁺) calcd for C₂₆H₂₈O₈S₂: 550.1564; found: 220.1559.

(4*RS*,6*SR*)-2-Phenyl-4,6-bis(2-phenyl-1,3-dithian-2-yl) methyl-1,3-dioxane (4)

2-Phenyl-1,3-dithiane (528 mg, 0.27 mmol) in dry THF (4 mL) was added dropwise over 10 min into a freshly prepared LDA solution in THF (from 2.7 mmol of diisopropylamine and *n*-BuLi at -40 °C under argon, followed by DMPU (0.24 mL, 2.0 mmol)). After addition of **3** (358 mg, 0.67 mmol in THF) the mixture was stirred at 0 °C for 6 h. Quenching the reaction with satd. NH_4Cl (3 mL) was followed by warming to room temperature, washing with satd. NaCl (3 × 3 mL) and water, drying and concentrating, which gave the crude product. Purification by column chromatography (hexane/EtOAc 15:1) afforded 4 as a white solid, m.p. 53 °C.

Yield: 301 mg (78%). IR (KBr) 3057, 2906, 1594, 1486, 1277, 1028, 909, 732, 701 cm⁻¹; ¹H NMR: δ = 7.93 (4H, d, *J* = 7.6 Hz), 7.36 (4H, t, *J* = 8 Hz), 7.27-7.22 (5H, m), 7.17-7.15 (2H, m), 5.18 (1H, s), 3.84-3.80 (2H, m), 2.71-2.67 (8H, m), 2.46 (2H, dd, *J* = 14.8, 6.8 Hz), 2.05 (2H, dd, *J* = 15.2, 2.8 Hz), 1.92-1.90 (4H, m), 1.35-1.17 (2H, m). ¹³C NMR: δ = 141.6, 138.3, 128.7, 128.5, 127.9, 127.6, 125.9, 9.2, 72.9, 57.3, 50.6, 38.3, 27.63, 27.59, 24.75. HRMS (ESI): *m/z* (M+H⁺) calcd for C₃₂H₃₆O₂S₄ : 581.1671; found: 581.1669.

(2*SR*,4*RS*)-1,5-Bis(2-phenyl-1,3-dithian-2-yl)pentane-2,4-diol (5)

Compound 4 (291 mg, 0.503 mmol) was dissolved in 80% acetic acid (15 mL) and warmed at 60 °C for 12 h. After neutralization with 3N NaOH, it was extracted with EtOAc (3×10 mL), washed with brine, dried over anhydrous Na₂SO₄ and chromatographed (hexane/EtOAc 4:1) to yield **5** as a colorless oil.

Yield: 183 mg (74%). IR (KBr) 3445, 3056, 2905, 1594, 1484, 1099, 909, 732, 701 cm⁻¹. ¹H NMR: δ = 7.87 (4H, d, *J* = 7.6 Hz), 7.40-7.26 (6H, m), 3.91-3.86 (2H, m), 3.09 (2H, s), 2.74-2.69 (8H, m), 2.24 (2H, dd, *J* = 14.8, 7.6 Hz), 1.99-1.92 (6H, m), 1.46-1.42 (1H, m), 1.1-1.05 (1H, m); ¹³C NMR: δ = 141.7, 128.8, 128.3, 127.3, 68.5, 57.3, 52.1, 44.2, 27.74, 27.39, 24.7. HRMS (ESI): *m/z* (M+Na⁺) calcd for C₂₅H₃₂O₂S₄: 515.1177; found: 515.1167.

(3*SR*,5*RS*)-3,5-Dihydroxy-1,7-diphenylheptane-1,7dione (6)

Compound 5 (126 mg, 0.26 mmol) was dissolved in a mixture of MeCN and satd. NaHCO₃ (6 mL, 1:1), kept at 0 $^{\circ}$ C, and treated with I₂ (260 mg, 1.02 mmol) for 45 min, and quenched with satd. Na₂S₂O₃/NaHCO₃ (6 mL, 1:1). The aqueous phase was extracted with EtOAc (3 × 10 mL), dried over anhydrous Na₂SO₄, and purified by column chromatography (hexane/EtOAc 2:1) to furnish **6** as a colorless oil.

Yield: 51 mg (64%). IR (KBr) 3432, 3061, 2924, 1679, 1448, 1212, 754, 691 cm⁻¹. ¹H NMR: δ = 7.97-7.95 (4H, m), 7.61-7.57 (2H, m), 7.50-7.46 (5H, m), 4.61-4.55 (2H, m), 4.03 (2H, br), 3.21-3.19 (4H, m), 1.85-1.81 (2H,

Article

m), 1.64 (2H, br); ¹³C NMR: $\delta = 200.1$, 136.7, 133.6, 128.69, 128.11, 68.1, 45.3, 41.9. HRMS (ESI): m/z (M+Na⁺) calcd for C₁₉H₂₄O₄: 335.1254; found: 335.1257. (*3SR*,*5RS*)-3,5-*O*-Benzylidene-1,7-diphenylheptane-1,7-dione (7)

Compound 4 (55 mg, 95 μ mol) and HgO (83 mg, 0.38 mmol) was dissolved in aqueous THF (2.3 mL, 15% H₂O) under argon, treated with BF₃ etherate (40 μ L, 0.38 mmol) and stirred at room temperature for 1.5 h. After filtration through celite the reaction mixture was washed with EtOAc (3 × 5 mL) and chromatographed (hexane/EtOAc 6:1) to afford 7 as a white solid, m.p. 72 °C.

Yield: 31 mg (82%). IR (KBr) 3381, 3056, 2917, 1958, 1684, 1350, 1112, 753, 693 cm⁻¹. ¹H NMR: δ = 7.98 (4H, d, *J* = 7.2 Hz), 7.58 (2H, t, *J* = 7.2Hz), 7.49-7.45 (4H, m), 7.39-7.28 (5H, m), 5.67 (1H, s), 4.65-4.60 (2H, m), 3.50 (2H, dd, *J* = 16.4, 6.4 Hz), 3.08 (2H, dd, *J* = 16.4, 6.4 Hz), 2.06 (1H, d, *J* = 12.8 Hz), 1.61 (1H, d, *J* = 12.8 Hz); ¹³C NMR: δ = 197.5, 138.3, 137.2, 133.4, 128.71, 128.37, 128.19, 126.1, 100.8, 73.3, 44.8, 37.1. HRMS (ESI): *m/z* (M+NH₄⁺) calcd for C₂₆H₂₄O₄: 418.2013; found: 418.2018. **Yashabushidiol A (8)**

Compound 7 (19 mg, 48 μ mol) and 29 mg (20%) Pd(OH)₂/C was saturated with hydrogen in 3.5 mL of EtOH, stirred at 35 °C for 3.5 h. The mixture was filtered through celite and chromatographed (hexane/EtOAc 2:1) to afford yashabushidiol A (8) as a colorless oil.

Yield: 10 mg (73%). IR (KBr) 3347, 2933, 1494, 1452, 1104, 746, 699 cm⁻¹. ¹H NMR (600 MHz): δ = 7.29-7.25 (4H, m), 7.20-7.18 (6H, m), 3.89-3.85 (2H, m), 2.94 (2H, s), 2.78-2.74 (2H, m), 2.74-2.65 (2H, m), 1.84-1.74 (4H, m), 1.64-1.54 (2H, m); ¹³C NMR: δ = 141.8, 128.44, 128.39, 125.9, 72.4, 43.0, 39.7, 31.6. HRMS (ESI): *m/z* (M+H⁺) calcd for C₁₉H₂₄O₂: 285.1849; found: 285.1843.

(±)-Diospongin A

To the solution of **6** (16 mg, 51 μ mol) in dry CH₂Cl₂ (4 mL) was added Et₃SiH (0.16 mL, 1 mmol), cooled to -18 °C, and then TMSOTf (11 μ L). After 15 min, the reaction was quenched with saturated NaHCO₃ (1 mL) and the aqueous phase was extracted with ethyl ether (3 × 5 mL). The combined organic extract was washed with water and brine, dried over anhydrous Na₂SO₄, and purified by column chromatography (hexane/EtOAc 2:1) to yield diospongin A as a colorless oil.

Yield: 6.4 mg (42%). IR (KBr) 3407, 3061, 2922, 1679, 1212, 1060, 751, 695 cm⁻¹. ¹H NMR: δ = 8.0-7.98 (2H, m), 7.58-7.44 (3H, m), 7.30-7.22 (5H, m), 4.93 (2H,

Ho et al.

dd, J = 11.6, 2 Hz), 4.68-4.61 (1H, m), 4.38 (1H, s), 3.42 (1H, dd, J = 16, 5.6 Hz), 3.06 (1H, dd, J = 16, 6.8 Hz), 2.04-1.94 (2H, m), 1.8-1.66 (2H, m), 1.60 (1H, br), 1.55 (4H, s); ¹³C NMR: $\delta = 198.2, 142.7, 137.4, 133.1, 128.5, 128.3, 128.3, 127.2, 125.8, 73.8, 69.1, 64.7, 45.2, 40.1, 38.5.$ HRMS (EI): m/z (M+H⁺) calcd for C₁₉H₂₀O₃: 297.1485; found 297.1479.

ACKNOWLEDGEMENTS

We are grateful to the National Natural Science Foundation (NSFC, 20772051) and the Ministry of Education (Program "111" and NCET-05-0880), People's Republic of China, for financial support.

REFERENCES

- 1. Jacobsen, E. N. Acc. Chem. Res. 2000, 33, 421.
- Trost, B. M.; Malhotra, S.; Mino, T.; Rajapaksa, N. S. *Chem. Eur. J.* 2008, *14*, 7648-7657.
- Fournier, P.-A.; Savoie, J.; Stenne, B.; Bedard, M.; Grandbois, A.; Collins, S. K. *Chem. Eur. J.* 2008, 14, 8690-8695.
- 4. Ho, T.-L. *Symmetry. A Basis for Synthesis Design*; Wiley: New York, 1995.
- Yin, J.; Konda, K.; Yasuhiro, T.; Tran, Q. L.; Miyahara, T.; Chen, Y.; Kadota, S. *Planta Med.* 2004, 70, 54.
- (a) Kawai, N.; Hande, S. M.; Uenishi, J. *Tetrahedron* 2007, 63, 9049-9056; (b) Sawant, K. B.; Jennings, M. P. J. Org. Chem. 2006, 71, 7911-7914; (c) Bressy, C.; Allais, F.; Cossy, J. Synlett 2006, 3455-3456; (c) Bates, R. W.; Song, P. Tetrahedron 2007, 63, 4497-4499; (d) Yadav, J. S.; Padmavani, B.; Reddy, B.V. S.; Venugopal, C.; Rao, A. B. Synlett 2007, 2045-2048; (e) Hiebel, M.-A.; Pelotier, B.; Piva, O. Tetrahedron 2007, 63, 7874-7878. (f) Lee, K.; Kim, H.; Hong, J. Org. Lett. 2009, 11, 5202-5205.
- Hashimoto, T.; Tori, M.; Asakawa, Y. Chem. Pharm. Bull. 1986, 34, 1846-1849.
- Narasimhulu, M.; Reddy, T. S.; Mahesh, K. C.; Krishna, A. S.; Rao, J. V.; Venkateswarlu, Y. *Bioorg. Med. Chem. Lett.* 2009, 19, 3125-3127.
- Carreno, M. C.; Des Mazery, R.; Urbano, A.; Colobert, F.; Solladié, G. J. Org. Chem. 2003, 68, 7779-7787.
- Boydell, A. J.; Jeffery, M. J.; Bürkstümmer, E.; Linclau, B. J. Org. Chem. 2003, 68, 8252-8255.
- Leo, M. H.; Leung, V. G.; Bruno, L. *Tetrahedron: Asymmetry* 2005, *16*, 2449-2453.
- Ley, S. V.; Anthony, N. J.; Armstrong, A.; Brasca, M. G.; Clarke, T.; Culshaw, D.; Greck, C.; Grice, P.; Jones, A. B.; Lygo, B.; Madin, A.; Sheppard, R. N.; Slawin, A. M. Z.; Williams, D. J. *Tetrahedron* 45, 1989, 7161-7194.
- Babler, J. H.; Malek, N. C.; Coghlan, M. J. J. Org. Chem. 1978, 43, 1821-1823.
- 14. Vedejs, E.; Fuchs, P. L. J. Org. Chem. 1971, 36, 366-367.